Drugs Made In America Acquisition II Corp. Ordinary Shares
NASDAQ Global MarketTotal Valuation
Drugs Made In America Acquisition II Corp. Ordinary Shares carries a market capitalization of 529.87M, placing it among publicly traded companies globally.
| Market Cap | 529.87M |
| Enterprise Value | N/A |
Share Statistics
Drugs Made In America Acquisition II Corp. Ordinary Shares currently has 63.70M shares outstanding.
| Shares Outstanding | 63.70M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Drugs Made In America Acquisition II Corp. Ordinary Shares trades at a trailing price-to-earnings ratio of 54.25.
| PE Ratio | 54.25 |
| PS Ratio | N/A |
| PB Ratio | 0.95 |
| P/TBV Ratio | 0.95 |
| P/FCF Ratio | -419.30 |
| P/OCF Ratio | -419.30 |
Financial Position
Drugs Made In America Acquisition II Corp. Ordinary Shares maintains a current ratio of 0.53, meaning it holds 0.5x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 0.53 |
| Quick Ratio | 0.52 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | 3.37 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Drugs Made In America Acquisition II Corp. Ordinary Shares's stock has gained approximately 2.12551% over the past 52 weeks. The 50-day moving average sits at 10.05, while the 200-day moving average is 9.99.
| Beta (5Y) | N/A |
| 52-Week Price Change | 2.12551% |
| 50-Day Moving Average | 10.05 |
| 200-Day Moving Average | 9.99 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -1.34M, while operating income came in at -1.34M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -1.34M |
| Pretax Income | 8.58M |
| Net Income | 8.58M |
| EBITDA | -1.34M |
| EBIT | -1.34M |
| Earnings Per Share (EPS) | 0.18 |
Balance Sheet
Total book value stands at 491.56M, with working capital of -314,524.00 providing operational flexibility.
| Cash & Cash Equivalents | 347,720.00 |
| Total Debt | N/A |
| Net Debt | 102,280.00 |
| Equity (Book Value) | 491.56M |
| Book Value Per Share | 10.52 |
| Working Capital | -314,524.00 |
Cash Flow
Drugs Made In America Acquisition II Corp. Ordinary Shares produced -1.11M in operating cash flow over the past twelve months.
| Operating Cash Flow | -1.11M |
| Capital Expenditures | N/A |
| Free Cash Flow | -1.11M |
| FCF Per Share | -0.02 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -107.67 |
| FCF Yield | -0.24 |
Scores
Drugs Made In America Acquisition II Corp. Ordinary Shares posts an Altman Z-Score of 15.32, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 15.32 |